Search Results
Homologous Recombination Deficient Diagnosis and PARP Inhibitor Therapy | Webinar | Ambry Genetics
What is HRD (Homologous Recombination Deficiency) and how does it impact ovarian cancer?
Genetic Testing for Prostate Cancer: Advances and Considerations | Webinar | Ambry Genetics
Next-Generation Sequencing (NGS) Assessment of Homologous Recombination Deficiency (HRD)...
PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry Genetics
Mark Landers -Development of selection strategies for Homologous Recombination Deficient...
PARP Inhibitors in Ovarian Cancer Treatment | Webinar | Ambry Genetics
ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander
Ask the Experts: HRD and Genetics
A Webinar on PARP Inhibitors in Epithelial Ovarian Cancer
Prevalence of homologous recombination deficiency among 53,000 tumour samples
Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian Cancer
